5MPA.SG - Midatech Pharma Plc

Stuttgart - Stuttgart Delayed price. Currency in EUR
-0.025 (-2.907%)
At close: 4:30PM CET
Stock chart is not supported by your current browser
Previous close0.860
Bid0.000 x 100000
Ask0.000 x 100000
Day's range0.835 - 0.845
52-week range0.112 - 1.751
Avg. volume46
Market cap27.686M
PE ratio (TTM)N/A
EPS (TTM)-1.332
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire15 days ago

    Midatech receives confirmation that its Q-Octreotide (MTD201) first in-human EU study is approved

    Midatech (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products in oncology, today announces it has received oral confirmation from Polish regulators that its first in-human study of its sustained release product octreotide MTD201 is approved.  Formal written confirmation of the approval is expected within the next two weeks. Q-Octreotide (MTD201) is Midatech's treatment for carcinoid cancer and acromegaly built on its Q-SpheraTM sustained release platform technology. The somatostatin analogue treatment for carcinoid cancer and acromegaly is being developed as the first alternative version of the commercial leading product, Sandostatin® LAR (SLAR).

  • Globe Newswire22 days ago

    Midatech Loan Agreement with MidCap Financial

    2 January 2018Midatech Pharma PLC("Midatech" or the "Company") Midatech enters into a Loan Agreement with MidCap Financial

  • We're sorry this is all we were able to find about this topic.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes